Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst

May 18, 2022 11:05 AM ETGalmed Pharmaceuticals Ltd. (GLMD)By: Mary Christine Joy, SA News Editor2 Comments
  • Galmed Pharmaceuticals (NASDAQ:GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without a price target.
  • The company had reported Q1 GAAP EPS of -$0.24, beats by $0.08.
  • H.C. Wainwright had downgraded the Israel-based company to Neutral earlier in the month, citing, among other things, uncertainty in its research into liver disease, non-alcoholic steato-hepatitis (NASH).

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.